[HIV drug resistance and optimization of antiviral treatment in resource-poor countries].
HIV drug resistance has been associated with treatment failure in Western countries but the lessons learned can be useful in optimization of highly active antiretroviral treatment (HAART) in resource-poor settings. There is a need to improve access to HAART in such regions, but appropriate strategies must be rapidly implemented, such as adapted programs to facilitate adherence to therapy, rational use of genotypic drug resistance monitoring in specific situations, and use of alternative treatment regimens. The implications of HIV genetic diversity must also be considered in management of drug resistance.
Centre Sida de l'Université McGill, Institut Lady Davis de Recherches médicales, Hôpital Général Juif Sir Mortimer B. Davis, 3755, chemin de la Côte Sainte-Catherine, Montréal, Québec, H3T 1E2 Canada.
Florence
F
Doualla-Bell
Dan
D
Turner
Hugues
H
Loemba
Marco
M
Petrella
Bluma
B
Brenner
Mark A
MA
Wainberg
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D005838:Genotype; D006678:HIV / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D011379:Prognosis
D019380:Anti-HIV Agents